Emergence of neutralizing antibodies associates with clearance of SARS-CoV-2 during HIV-mediated immunosuppression
To design effective vaccines and other immune interventions against a pathogen, it is necessary to know which aspect of immunity associates with protection. We investigated whether neutralizing antibodies associate with infection clearance in long-term SARS-CoV-2 infection during HIV-mediated immunosuppression. We monitored neutralizing antibody activity against SARS-CoV-2 over 1 to 2 years in five participants with advanced HIV disease and delayed control of HIV viremia. These participants had persistent SARS-CoV-2 infection ranging from 110 to 289 days which was associated with low or undetectable neutralizing antibody responses. SARS-CoV-2 clearance was associated with the emergence of neutralizing antibodies and occurred in two participants before suppression of HIV viremia, but after some CD4 T cell reconstitution. Vaccination only further increased neutralizing antibody levels in the advanced HIV disease participants who achieved HIV suppression pre-vaccination. During the prolonged SARS-CoV-2 infection we observed widespread evolution which was particularly pronounced in one Delta variant infection. This resulted in high-level escape from Delta-elicited neutralizing antibodies and a virus antigenically distinct from both ancestral SARS-CoV-2 and Omicron XBB in hamster experimental infections. The results offer new evidence that neutralizing antibodies associate with SARS-CoV-2 clearance and argue that successful management of HIV may be necessary to curtail long-term infection and evolution of co-infecting pathogens..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 23. Aug. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karim, Farina [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.08.18.23293746 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI040587886 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI040587886 | ||
| 003 | DE-627 | ||
| 005 | 20231205144348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230822s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.08.18.23293746 |2 doi | |
| 035 | |a (DE-627)XBI040587886 | ||
| 035 | |a (biorXiv)10.1101/2023.08.18.23293746 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karim, Farina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emergence of neutralizing antibodies associates with clearance of SARS-CoV-2 during HIV-mediated immunosuppression |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a To design effective vaccines and other immune interventions against a pathogen, it is necessary to know which aspect of immunity associates with protection. We investigated whether neutralizing antibodies associate with infection clearance in long-term SARS-CoV-2 infection during HIV-mediated immunosuppression. We monitored neutralizing antibody activity against SARS-CoV-2 over 1 to 2 years in five participants with advanced HIV disease and delayed control of HIV viremia. These participants had persistent SARS-CoV-2 infection ranging from 110 to 289 days which was associated with low or undetectable neutralizing antibody responses. SARS-CoV-2 clearance was associated with the emergence of neutralizing antibodies and occurred in two participants before suppression of HIV viremia, but after some CD4 T cell reconstitution. Vaccination only further increased neutralizing antibody levels in the advanced HIV disease participants who achieved HIV suppression pre-vaccination. During the prolonged SARS-CoV-2 infection we observed widespread evolution which was particularly pronounced in one Delta variant infection. This resulted in high-level escape from Delta-elicited neutralizing antibodies and a virus antigenically distinct from both ancestral SARS-CoV-2 and Omicron XBB in hamster experimental infections. The results offer new evidence that neutralizing antibodies associate with SARS-CoV-2 clearance and argue that successful management of HIV may be necessary to curtail long-term infection and evolution of co-infecting pathogens. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Bernstein, Mallory |4 aut | |
| 700 | 1 | |a Jule, Zesuliwe |4 aut | |
| 700 | 1 | |a Lustig, Gila |4 aut | |
| 700 | 1 | |a Upton, Janine-Lee |4 aut | |
| 700 | 1 | |a Ganga, Yashica |4 aut | |
| 700 | 1 | |a Khan, Khadija |4 aut | |
| 700 | 1 | |a Reedoy, Kajal |4 aut | |
| 700 | 1 | |a Mazibuko, Matilda |4 aut | |
| 700 | 1 | |a Govender, Katya |4 aut | |
| 700 | 1 | |a Thambu, Kershnee |4 aut | |
| 700 | 1 | |a Ngcobo, Nokuthula |4 aut | |
| 700 | 1 | |a Venter, Elizabeth |4 aut | |
| 700 | 1 | |a Makhado, Zanele |4 aut | |
| 700 | 1 | |a Hanekom, Willem |4 aut | |
| 700 | 1 | |a von Gottberg, Anne |4 aut | |
| 700 | 1 | |a Karim, Quarraisha Abdool |4 aut | |
| 700 | 1 | |a Abdool Karim, Salim S. |4 aut | |
| 700 | 1 | |a Manickchund, Nithendra |4 aut | |
| 700 | 1 | |a Magula, Nombulelo |4 aut | |
| 700 | 1 | |a Gosnell, Bernadett I. |4 aut | |
| 700 | 1 | |a Moore, Penny L. |4 aut | |
| 700 | 1 | |a Lessells, Richard J. |4 aut | |
| 700 | 1 | |a de Oliveira, Tulio |0 (orcid)0000-0002-3027-5254 |4 aut | |
| 700 | 1 | |a Moosa, Mahomed-Yunus S. |4 aut | |
| 700 | 1 | |a Sigal, Alex |0 (orcid)0000-0001-8571-2004 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 23. Aug. |
| 773 | 1 | 8 | |g year:2023 |g day:23 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.08.18.23293746 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 23 |c 08 | ||